Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11498052 | 0.81 | ALOX15 (0.41) | ALOX15 | |
| SCHEMBL1302638 | 0.79 | ALOX15 (0.44) | ALOX15 | |
| SCHEMBL2049118 | 0.78 | ALOX15 (0.35) | ALOX15 | |
| SCHEMBL301115 | 0.77 | ALOX15 (0.39) | ALOX15MEN1CYP3A4KMT2A | |
| SCHEMBL11005598 | 0.76 | ALOX15 (0.41) | ALOX15 | |
| SCHEMBL3109209 | 0.76 | ALOX15 (0.41) | ALOX15 | |
| SCHEMBL772676 | 0.75 | MEN1 (0.32) | ALOX15MEN1CYP3A4KMT2A | |
| SCHEMBL772677 | 0.75 | MEN1 (0.32) | ALOX15MEN1CYP3A4KMT2A | |
| SCHEMBL28553751 | 0.75 | ALOX15 (0.40) | ALOX15 | |
| SCHEMBL4413348 | 0.75 | ALOX15 (0.40) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303019-A1 | TOPICAL SKIN CARE FORMULATION | MARY KAY INC. | 2016-10-20 | — | — | US | claimed |
| US-9402794-B2 | Topical skin care formulation | MARY KAY INC. (US) | 2016-08-02 | — | — | US | claimed |
| US-8318222-B2 | Topical skin care formulation | MARY KAY, INC. (US) | 2012-11-27 | — | — | US | claimed |
| US-8039011-B2 | A temperature change composition including a neurosensory component, e.g., menthol, and a first phase change component having a first phase change temperature between 15-40 degrees C., e.g., hydrocarbon, wax; encapsulated evaporative cooling agent; refreshing; durability; receptivity with other skin item | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-20110206793-A1 | TOPICAL SKIN CARE FORMULATION | MARY KAY INC. (US) | 2011-08-25 | — | — | US | claimed |
| EP-2207524-A2 | SKIN COOLING COMPOSITION | Kimberly-Clark Worldwide, Inc. (US) | 2010-07-21 | — | — | EP | claimed |
| EP-2059229-A2 | SKIN COOLING COMPOSITIONS | Kimberly-Clark Worldwide, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2009057000-A2 | SKIN COOLING COMPOSITION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2009-05-07 | — | — | WO | claimed |
| US-20090110656-A1 | Skin cooling composition | KIMBERLY-CLARK WORLDWIDE, INC. | 2009-04-30 | — | — | US | claimed |
| WO-2008044154-A2 | SKIN COOLING COMPOSITIONS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-04-17 | — | — | WO | claimed |
| US-20080085290-A1 | Skin cooling compositions | KIMBERLY-CLARK WORLDWIDE, INC. | 2008-04-10 | — | — | US | claimed |
| US-12605308-B2 | Topical skin care formulations comprising plant extracts | MARY KAY INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260000603-A1 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | MARY KAY INC. (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4592279-A2 | MYELINATION STIMULATOR COMPOUNDS, AND METHODS OF TREATMENT | University of Florida Research Foundation, Incorporated (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-3813824-B1 | USE OF MYELINATION STIMULATOR COMPOUNDS | UNIV FLORIDA (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-2059229-A2 | SKIN COOLING COMPOSITIONS | Kimberly-Clark Worldwide, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2009057000-A2 | SKIN COOLING COMPOSITION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090110656-A1 | Skin cooling composition | KIMBERLY-CLARK WORLDWIDE, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2008044154-A2 | SKIN COOLING COMPOSITIONS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20080085290-A1 | Skin cooling compositions | KIMBERLY-CLARK WORLDWIDE, INC. | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000603-A1 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | CUTA, TYR, FLNA | ALOX15 1549/4885MEN1 4738/4885CYP3A4 930/4885 |
| US-12605308-B2 | Topical skin care formulations comprising plant extracts | MMP9, MMP1, MMP2 | ALOX15 267/4885MEN1 3240/4885CYP3A4 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.